Barcelo Alberto, Arredondo Armando, Gordillo-Tobar Amparo, Segovia Johanna, Qiang Anthony
University of Miami, Miller School of Medicine, Miami, Florida, USA.
National Institute of Public Health, Cuernavaca, Mexico.
J Glob Health. 2017 Dec;7(2):020410. doi: 10.7189/jogh.07.020410.
The financial implications of the increase in the prevalence of diabetes in middle-income countries represents one of the main challenges to health system financing and to the society as a whole. The objective of this study was to estimate the economic cost of diabetes in Latin America and the Caribbean (LAC) in 2015.
The study used a prevalence-based approach to estimate the direct and indirect costs related to diabetes in 29 LAC countries in 2015. Direct costs included health care expenditures such as medications (insulin and oral hypoglycemic agents), tests, consultations, hospitalizations, emergency visits and treating complications. Two different scenarios (S1 and S2) were used to analyze direct cost. S1 assumed conservative estimates while S2 assumed broader coverage of medication and services. Indirect costs included lost resources due to premature mortality, temporary and permanent disabilities.
In 2015 over 41 million adults (20 years of age and more) were estimated to have Diabetes Mellitus in LAC. The total indirect cost attributed to Diabetes was US$ 57.1 billion, of which US$ 27.5 billion was due to premature mortality, US$16.2 billion to permanent disability, and US$ 13.3 billion to temporary disability. The total direct cost was estimated between US$ 45 and US$ 66 billion, of which the highest estimated cost was due to treatment of complications (US$ 1 616 to US$ 26 billion). Other estimates indicated the cost of insulin between US$ 6 and US$ 11 billion; oral medication US$ 4 to US$ 6 billion; consultations between US$ 5 and US$ 6 billion; hospitalization US$ 10 billion; emergency visits US$ 1 billion; test and laboratory exams between US$ 1 and US$ 3 million. The total cost of diabetes in 2015 in LAC was estimated to be between US$ 102 and US$ 123 billion. On average, the annual cost of treating one case of diabetes mellitus (DM) in LAC was estimated between US$ 1088 and US$ 1818. Per capita National Health Expenditures averaged US$ 1061 in LAC.
Diabetes represented a major economic burden to the countries of Latin America and the Caribbean in 2015. The estimates presented here are key information for decision-making that can be used in the formulation of policies and programs to achieve greater efficiency and effectiveness in the use of resources for diabetes prevention in the 29 countries of LAC.
中等收入国家糖尿病患病率上升所带来的经济影响是卫生系统融资乃至整个社会面临的主要挑战之一。本研究的目的是估算2015年拉丁美洲和加勒比地区(LAC)糖尿病的经济成本。
该研究采用基于患病率的方法来估算2015年29个LAC国家与糖尿病相关的直接和间接成本。直接成本包括医疗保健支出,如药物(胰岛素和口服降糖药)、检查、会诊、住院、急诊以及治疗并发症的费用。采用两种不同的情景(S1和S2)来分析直接成本。S1采用保守估计,而S2假定药物和服务的覆盖范围更广。间接成本包括因过早死亡、暂时和永久残疾导致的资源损失。
2015年,估计LAC地区有超过4100万成年人(20岁及以上)患有糖尿病。糖尿病所致的间接成本总计571亿美元,其中275亿美元归因于过早死亡,162亿美元归因于永久残疾,133亿美元归因于暂时残疾。直接成本估计在450亿至660亿美元之间,其中估计最高的成本是治疗并发症(161.6亿至260亿美元)。其他估计表明,胰岛素成本在60亿至110亿美元之间;口服药物40亿至60亿美元;会诊50亿至60亿美元;住院100亿美元;急诊10亿美元;检查和实验室检查100万至300万美元。2015年LAC地区糖尿病的总成本估计在1020亿至1230亿美元之间。平均而言,LAC地区治疗一例糖尿病(DM)的年度成本估计在1088美元至1818美元之间。LAC地区人均国家卫生支出平均为1061美元。
2015年糖尿病给拉丁美洲和加勒比地区国家带来了重大经济负担。这里给出的估计是决策的关键信息,可用于制定政策和计划,以提高LAC地区29个国家在糖尿病预防资源利用方面的效率和效果。